Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Overview
CoChat Summary
TL;DR
An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.
Key findings
- For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
- For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
- TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
- In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).
Methods
- Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
- Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
- Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.
Limitations
- The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
- The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
- Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
In type 1 diabetes, the Results (Table 2; page unavailable) show weaker correlations for hypoglycemia and glycemic variability than for mean glucose at 15 days. But they also show that both correlations increase as sampling extends from 3 to 15 days, contrary to the citing sentence’s claim that an increase with longer sampling has not been shown. The paper does not frame this analysis as >70% CGM use over 14 days. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that correlations with the full three-month data increased as sampling lengthened for both hypoglycemia and glycemic variability. From 3 to 15 days, r² rose from 0.32 to 0.66 for values ≤70 mg/dL and from 0.36 to 0.70 for coefficient of variation—the opposite of the attributed claim. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The first longitudinal CGM data demonstrated a 13percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61).”
What the sources say
- Disputedcites [61] 62. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med. 2016;375(7):644-654. sourceExperimental — accuracy not yet measured
The Study Outcomes report different CGM time-in-range results: 59.5% to 74.7% overnight and 56.8% to 66.3% over 24 hours with closed-loop therapy. The paper defines its target range as 63–140 mg/dL, not 70–140 mg/dL; it does not report the claimed increase from 43% to 56%. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Partly supportedcites [2] 2. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 2017;40(4):538-545. sourceExperimental — accuracy not yet measured
The Introduction reports that several randomized trials found CGM benefits, including reduced HbA1c and hypoglycemia, particularly in adults with type 1 diabetes. But the Conclusions say this trial included only insulin-pump users; extending its results to people using injections is described as reasonable, not demonstrated. The paper therefore does not establish benefits regardless of insulin delivery method or across all people with diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Not checked — no full text of the sourcecites [5] 5. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, for the DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017; 40:736-741. source
- Supportedcites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. source
The Discussion reports significant glycemic benefits from real-time CGM that were comparable with pump (CSII) and injection (MDI) therapy. The study concerns people with type 1 diabetes. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [7] 7. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, openlabel, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893-902. source
- Not checked — no full text of the sourcecites [8] 8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263. source
- Partly supportedcites [9] 9. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulintreated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. sourceExperimental — accuracy not yet measured
The Results report significant reductions in hypoglycemic events with flash glucose monitoring in adults with insulin-treated type 2 diabetes, supporting a clinical benefit. The Results also state that 95% of participants used an insulin pen or syringe and 5% used continuous subcutaneous insulin infusion; the paper does not establish that the benefit held regardless of insulin delivery method. No page numbers are available in our copy. (LLM, conf=0.85)
- Partly supportedcites [10] 10. Choudhary P, Olsen BS, Conget I, et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18(5):288-291. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the CGM-based MiniMed 640G pump system can help patients with type 1 diabetes avoid hypoglycemia. But this short, uncontrolled study examined a predictive pump-suspension system, not CGM use regardless of insulin delivery method; it does not establish a benefit across delivery methods or isolate the benefit of CGM itself. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Could not verifycites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. sourceExperimental — accuracy not yet measured
The Prespecified outcomes section (page unavailable) identifies HbA1c as this type 1 diabetes study’s primary endpoint. Neither that section nor the Discussion passages establish that A1C is the key surrogate marker for long-term complications in people with both type 1 and type 2 diabetes. Searches for that surrogate-marker relationship and for complications found no passage stating it. (LLM, conf=0.72)
- Partly supportedcites [33] 32. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55(12):3155-3162. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links near-normal glycaemia with reduced complication risk in type 1 diabetes, and Methods > Outcome measure (page unavailable) uses HbA1c as this trial’s primary endpoint. The paper does not establish HbA1c as the key surrogate marker for long-term complications in both type 1 and type 2 diabetes. (LLM, conf=0.81)
- Could not verifycites [32] 31. Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. Diabetes Care 2017;40:655 ʹ 662. sourceExperimental — accuracy not yet measured
The Baseline Assessment section says HbA1c was measured at the start of monitoring, but does not describe it as a surrogate marker for long-term complications. The Research Design and Methods section examines arrhythmias during hypoglycemia, not A1C as a primary endpoint in CGM studies. Searches for the surrogate-marker and primary-endpoint claims found no supporting passage in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 16 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the advent of newer studies of CGM in noninsulin‐treated individuals and increasing uptake, the utility of CGM is progressively being endorsed in this population.”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycaemia is associated with an increased risk of vascular events, explaining recent consensus advocating hypoglycaemic exposure at <1% (i.e.<15 min/day) in individuals at high CV risk.137,138”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering the older age of participants and comorbid conditions reported, the mean HbA1c, GMI, TIR, and TBR results (8.0%, 7.6%, 56%, and 1.0% at 6 months, respectively) demonstrate close adherence to established glycemic targets (23, 24, 38).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [193]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ FIGURES / TABLES · p. 4
“2 Figures / 3 Tables”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Time in Ranges · p. 11
“Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Cited by
Items 601–700 of 3,959
Varimo, T. J., Pulkkinen, M., Hakonen, E. T., Hero, M. T., Miettinen, P. J., & Tuomaala, A. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13235 · Cited by 31
“9 mmoL/L) of less than 4%, and CV of less than 36%.(2,3) Achieving these goals is challenging, especially in children and adolescents with T1D who commonly suffer from diabetes distress.”
BackgroundGoldenberg, R., Aroda, V. R., Billings, L. K., Christiansen, A. S. L., Donatsky, A. M., Rizi, E. P., Podgorski, G., Rašlová, K., Klonoff, D. C., & Bergenstal, R. M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14504 · Cited by 34
“All prespecified endpoint analyses were performed on a final analysis set comprising participants remaining on assigned treatment and completing ≥70% of 2 weeks' CGM measurements in each maintenance period (as recommended by the International Consensus on Time in Range).(5)”
BackgroundMethodInfluentialSelf-citationWin, M., Beckett, R., Thomson, L., Thankamony, A., & Beardsall, K. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab601 · Cited by 36
Morrison, D., Zaharieva, D. P., Lee, M. H., Paldus, B., Vogrin, S., Grosman, B., Roy, A., Kurtz, N., & O'Neal, D. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0221 · Cited by 32
Marks, B. E., Williams, K. M., Sherwood, J. S., & Putman, M. S. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100282 · Cited by 39
“Studies have shown that 70% TIR (16.8 h per day) is correlated with an A1c of 7% and International Consensus Guidelines therefore recommend a target of 70% TIR, 5% TBR (1.2 h per day), and 30% TAR (7.2 h) for most individuals with T1D and T2D [26,27].”
BackgroundInfluentialDe Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
“43%), thereby approaching the goal to spend more than 70% of time in the target range, as proposed by the CGM consensus panel.(79) CGM profiles showed consistent reductions in glucose both overnight and during the day.”
BackgroundPsoma, O., Makris, M., Tselepis, A. D., & Tsimihodimos, V. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221146808 · Cited by 32
Protein glycation in diabetes mellitus
Shin, A., Connolly, S. M., & Kabytaev, K. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.11.003 · Cited by 38
Tian, T., Aaron, R. E., Yeung, A. M., Huang, J. K., Drincic, A., Seley, J. J., Wallia, A., Gilbert, G. H., Spanakis, E. K., Masharani, U. B., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231186575 · Cited by 34
Self-citationZang, L., Li, Y., Hao, H., Liu, J., Zhang, Q., Gao, F., Wang, H., Chen, Y., Gu, W., Du, J., et al. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad060 · Cited by 37
“5 As a new accurate reflection of overall glycemic control, TIR has become an effective supplement to HbA1c and has been proved to be negatively correlated with diabetic chronic complications and cardiovascular death risk.”
BackgroundMita, T., Katakami, N., Okada, Y., Yoshii, H., Osonoi, T., Nishida, K., Shiraiwa, T., Kurozumi, A., Taya, N., Wakasugi, S., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06013-3 · Cited by 32
“Accordingly, in our participants, TIR was more than acceptable and CV was much lower than the target CGM-derived metrics proposed by an international consensus [27], suggesting that blood glucose in our participants was relatively well controlled.”
BackgroundMethodInfluentialThe Role of Systemic Family Psychotherapy in Glycemic Control for Children with Type 1 Diabetes
Sălcudean, A., & Lica, M. M. (2024) · Children · doi:10.3390/children11010104 · Cited by 29
“Improving the HbA1c values means paying more attention to the factors that influence it; that is, diet, correct establishment of insulin requirements, correct and frequent measurements of blood glucose, or the use of CGM (Continuous Glucose Monitoring), where possible [1,4].”
BackgroundPulkkinen, M., Varimo, T. J., Hakonen, E. T., Hero, M. T., Miettinen, P. J., & Tuomaala, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15562 · Cited by 34
Wang, Y., Lu, J., Yu, J., Ni, J., Wang, M., Lu, W., Zhu, W. M., Guo, J., Bao, Y., & Zhou, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16143 · Cited by 32
Ying, Z., Fan, Y., Chen, C., Liu, Y., Tang, Q., Chen, Z., Yang, Q., Yan, H., Wu, L., Lu, J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.8910 · Cited by 41
Embedded Model Predictive Control for a Wearable Artificial Pancreas
Chakrabarty, A., Healey, E., Shi, D., Zavitsanou, S., Doyle, F. J., & Dassau, E. (2019) · IEEE Transactions on Control Systems Technology · doi:10.1109/tcst.2019.2939122 · Cited by 31
“These quantities validate the performance and effectiveness of the embedded MPC despite the modifications and simplifications introduced to implement the ZMPC on an embedded system, as per the International consensus on clinical targets [46].”
MethodSelf-citationContinuous Glucose Monitoring–Derived Data Report—Simply a Better Management Tool
Battelino, T., & Bergenstal, R. M. (2020) · Diabetes Care · doi:10.2337/dci20-0032 · Cited by 28
“(15) represented as bars of the consensus Ambulatory Glucose Profile (18).”
BackgroundMethodSelf-citationLEVIN, P. A., Hoogwerf, B. J., Snell‐Bergeon, J. K., Vigers, T., Pyle, L. L., & Bromberger, L. A. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.10.004 · Cited by 32
Zhang, J., Yang, J., Liu, L., Li, L., Cui, J., Wu, S., & Tang, K. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00753-2 · Cited by 32
“clearly recommended as one of the core indicators of CGM report [13], and the commonly used indicators of blood glucose fluctuation include the following four indicators [14]: standard deviations of blood glucose (SDBG, calculation method: standard deviation of measured values during CGM monitoring), large amplitude o…”
MethodBoscari, F., Vettoretti, M., Cavallin, F., Amato, A. M. L., Uliana, A., Vallone, V., Avogaro, A., Facchinetti, A., & Bruttomesso, D. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01624-2 · Cited by 33
Hayek, A. A., Robert, A. A., & Dawish, M. A. A. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102265 · Cited by 31
Ferm, M. L., DeSalvo, D. J., Prichett, L. M., Sickler, J. K., Wolf, R. M., & Channa, R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.26126 · Cited by 33
Closed-Loop Insulin Therapy in Older Adults with Type 1 Diabetes: Real-World Data
Toschi, E., Atakov-Castillo, A., Slyne, C., & Munshi, M. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0311 · Cited by 28
Lambadiari, V., Saltik, A. Z. O., de Portu, S., Buompensiere, M. I., Kountouri, A., Korakas, E., Sharland, H., & Cohen, O. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0443 · Cited by 30
“0mmol/L), 17 which represents short-term glycemic control, compared with previous generation devices and other insulin delivery methods.”
Current Management of Glycemia in Children with Type 1 Diabetes Mellitus
Sperling, M. A., & Laffel, L. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmcp2112175 · Cited by 43
Self-citationLee, T., Collett, C., Man, M., Hammond, M., Shepstone, L., Hartnell, S., Gurnell, E. M., Byrne, C., SCOTT, E. M., Lindsay, R. S., et al. (2022) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-022-04543-z · Cited by 29
Self-citationRankin, D., Hart, R. I., Kimbell, B., Barnard-Kelly, K. D., Brackenridge, A., Byrne, C., Collett, C., Dover, A. R., Hartnell, S., Hunt, K. F., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0479 · Cited by 30
“8 mmol/L for at least 70% of the day.(1) Most women experience difficulties attaining these targets.”
BackgroundSelf-citationPast, Present, and Future of Continuous Glucose Monitors
Garg, S. K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0041 · Cited by 32
Self-citationMichaels, V. R., Boucsein, A., Watson, A. S., Frewen, C. M., Sanders, O. J., Haszard, J. J., Jones, S., Milford-Hughes, P. J., de Bock, M. I., & Wheeler, B. J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0334 · Cited by 28
Use of Glucose-Lowering Agents in Diabetes and CKD
Alicic, R. Z., Neumiller, J. J., Galindo, R. J., & Tuttle, K. R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.018 · Cited by 39
“, time-below range <1%).(72) Though CGM is a promising technology, there are limited studies in patients with CKD.”
BackgroundLameijer, A., Lommerde, N., Dunn, T. C., Fokkert, M. J., Edens, M. A., Kao, K., Xu, Y., Gans, R. O. B., Bilo, H. J. G., & van Dijk, P. R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108897 · Cited by 27
Acciaroli, G., Welsh, J. B., & Akturk, H. K. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820982584 · Cited by 27
“001 Duration (min) <70 48 (24) 40 (20) 17 <.”
Messika, A., Toledano, Y., Hadar, E., Shmuel, E., Tauman, R., Shamir, R., & Froy, O. (2022) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2022.100660 · Cited by 30
Huang, Y., Yue, L., Qiu, J., Gao, M., Liu, S., & Wang, J. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1880-0978 · Cited by 37
Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis
Wijewickrama, P. S. A., Williams, J. K., Bain, S. C., Dasgupta, I., Chowdhury, T. A., Wahba, M. M., Frankel, A., Lambie, M., & Karalliedde, J. J. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.01.040 · Cited by 29
Understanding temporal changes and seasonal variations in glycemic trends using wearable data
Belsare, P. V., Bartolome, A., Stanger, C., & Prioleau, T. (2023) · Science Advances · doi:10.1126/sciadv.adg2132 · Cited by 31
“To achieve this, we used clinical targets as a basis for stratifying subjects into three subgroups based on glycemic control ( 4 , 14 ).”
InfluentialThrasher, J. R., Arrieta, A., Niu, F., Cameron, K. R., Cordero, T. L., Shin, J., Rhinehart, A. S., & Vigersky, R. A. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0453 · Cited by 33
“37,38 were also calculated.”
Valent, A. M., Rickert, M. C., Pagan, C. H., Ward, L., DUNN, E. Z., & Rincon, M. P. (2025) · Diabetes Care · doi:10.2337/dc25-0115 · Cited by 44
Davies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 63
Irace, C., Cutruzzolà, A., Nuzzi, A., Assaloni, R., Brunato, B., Pitocco, D., Tartaglione, L., Molfetta, S. D., Cignarelli, A., Laviola, L., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13993 · Cited by 29
“was nearly at the guideline-directed goal of >70%.(19) These favourable results in the real-world clinical setting provide support for the use of a long-term, implantable CGM system to optimize the management of type I diabetes.”
ResultAronson, R., Brown, R. E., Abitbol, A., Goldenberg, R., Yared, Z., Ajala, B., & Yale, J.-F. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0204 · Cited by 27
“27 As seen in the other real-world reports, CGM/FGM users in this cohort showed no difference in glycemia between individuals using MDI versus CSII therapy.”
Warshaw, H. S., Isaacs, D. M., & MacLeod, J. (2020) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721720930183 · Cited by 29
“The goal is to have a CV <36%.(50) To calculate CV: SD / mean glucose × 100.”
BackgroundPleus, S., Stuhr, A., Link, M., Haug, C., & Freckmann, G. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821992373 · Cited by 28
Glucagon: Its evolving role in the management of hypoglycemia
Isaacs, D. M., Clements, J. N., Turco, N., & Hartman, R. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2534 · Cited by 31
Increased Hemoglobin A1c Time in Range Reduces Adverse Health Outcomes in Older Adults With Diabetes
Prentice, J. C., Mohr, D. C., Zhang, L., Li, D., Legler, A., Nelson, R. E., & Conlin, P. R. (2021) · Diabetes Care · doi:10.2337/dc21-0292 · Cited by 30
Ulrich, H., & Bowen, M. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.05.013 · Cited by 27
Hissa, M. R. N., Hissa, P. N. G., Guimarães, S. B., & Hissa, M. N. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00722-8 · Cited by 28
Schweiger, D. Š., Battelino, T., & Grošelj, U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910192 · Cited by 31
Self-citationFurthner, D., Lukas, A., Schneider, A. M., Mörwald, K., Maruszczak, K., Gombos, P., Gomahr, J., Steigleder-Schweiger, C., Weghuber, D., & Pixner, T. (2021) · Nutrients · doi:10.3390/nu13103558 · Cited by 27
“CGM should be routinely used as a time in range reflects the glucose levels better than single-point measurements [13].”
BackgroundInfluentialÖzaslan, B., Levy, C. J., Kudva, Y. C., Pinsker, J. E., O’Malley, G., Kaur, R. J., CASTORINO, K. N., Levister, C. M., Trinidad, M. C., Desjardins, D., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0521 · Cited by 28
“…targets for pregnant women with T1D should be guided by a time in range (TIR) goal of > 70% based on the glycemic target range of 63–140 mg/dL. 15 Despite increased adoption of CGM 16 and the use of more rapid insulin analogs 17 to assist in glycemic management, many pregnant women still…”
Self-citationOlsen, M. T., Dungu, A. M., Klarskov, C. K., Jensen, A. K., Lindegaard, B., & Kristensen, P. L. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-01874-7 · Cited by 27
Szmuilowicz, E. D., & Aleppo, G. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2110507 · Cited by 27
“Standardized CGM metrics with corresponding target ranges are shown in Table 2 [13].”
BackgroundInfluentialLong-term outcomes of an advanced hybrid closed-loop system: A focus on different subpopulations
Beato-Víbora, P. I., Ambrojo-López, A., Fernández-Bueso, M., Gil-Poch, E., & Arroyo-Díez, F. J. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110052 · Cited by 27
Software Packages and Tools for the Analysis of Continuous Glucose Monitoring Data
Piersanti, A., Giurato, F., Göbl, C. S., Burattini, L., Tura, A., & Morettini, M. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0237 · Cited by 33
“…therapies, as well as track the related improvements, will prefer those software packages that provide metrics and data visualization options recommended by the international consensus 17,18 ; from this analysis, the highest number of standard metrics is provided by cgmanalysis and iglu.”
IGUDESMAN, D. A., Crandell, J., Corbin, K. D., Zaharieva, D. P., Addala, A., Thomas, J. M., Casu, A., Kirkman, M. S., Pokaprakarn, T., Riddell, M. C., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14911 · Cited by 29
“Additional measurements that were analysed descriptively included the change in per of body fat, and, per CGM consensus guidelines, the changes in percentage of time above range (%TAR; 181-250 mg/dl and, separately, ≥250 mg/dl), as well as the coefficient of variation (CV).(16) Young adults meeting all eligibility cri…”
BackgroundMethodInfluentialChrzanowski, J., Grabia, S., Michalak, A., Wielgus, A., Wykrota, J., Mianowska, B., Szadkowska, A., & Fendler, W. M. (2022) · Diabetes Care · doi:10.2337/dc22-0534 · Cited by 36
Time-restricted eating improves measures of daily glycaemic control in people with type 2 diabetes
Parr, E. B., Steventon-Lorenzen, N., Johnston, R., Maniar, N., Devlin, B. L., Lim, K., & Hawley, J. A. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110569 · Cited by 35
Urakami, T., Yoshida, K., Kuwabara, R., Mine, Y., Aoki, M., Suzuki, J., & Morioka, I. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13618 · Cited by 26
Self-citationAronson, R., Abitbol, A., Bajaj, H. S., Cheng, A. Y. Y., Christopoulos, S., Harris, S. B., Jain, A. B., & Goldenberg, R. M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70008 · Cited by 33
“6 Given the need for an evidence-based review of CGM in people living with T2DM who are not using insulin, an expert forum was convened in April 2025 to critically examine the evidence on the role of CGM in noninsulin-treated T2DM settings.”
Continuous Glucose Monitoring Metrics in High-Risk Pregnant Women with Type 2 Diabetes
McLean, A., Barr, E., Tabuai, G., Murphy, H. R., & Maple-Brown, L. J. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0300 · Cited by 28
“13 Currently, there are guidelines for women with T1DM pregnancy: target HbA1c levels in the first trimester ( < 6.5%, < 48 mmol/mol) and third trimester ( < 6.1%, < 43 mmol/mol); CGM target glucose range 3.5–7.8 mmol/L (63–140 mg/dL) with time spent in range > 70% (i.e., > 16.8 h/day); time above…”
BackgroundInfluentialSelf-citationNielsen, B. U., Olsen, M. F., Mathiesen, I. H. M., Pressler, T., Ritz, C., Katzenstein, T. L., Olesen, H. V., Skov, M., Jensen‐Fangel, S., Almdal, T., et al. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.11.005 · Cited by 26
Heterogeneity of glycaemic phenotypes in type 1 diabetes
Fagherazzi, G., Aguayo, G., Zhang, L., Hanaire, H. P., Picard, S., Sablone, L., Vergès, B. L., Hamamouche, N., Detournay, B., Joubert, M., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06179-4 · Cited by 33
“…and with CGM data from a variety of different devices, depending on which system is used by the individual user: time below range (TBR) ( 3.9 mmol/l), TIR and CV. CGM data were captured within 14 days before inclusion according to the recommendations of an international consensus statement [20].”
InfluentialLim, B. S. Y., Yang, Q., Choolani, M. A., Gardner, D. S.-L., Chong, Y. S., Zhang, C., Chan, S., & Li, L. (2024) · Diabetes Care · doi:10.2337/dc24-0944 · Cited by 31
Saisho, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1776262 · Cited by 28
“time in range (TIR) has also been proposed as a new glycemic indicator [89,90].”
BackgroundDiabetes Management During Breastfeeding in Women with Type 1 Diabetes
Ringholm, L., STOUGAARD, E. B., Nørgaard, S. K., Damm, P., & Mathiesen, E. R. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01315-x · Cited by 28
Viñals, C., Mesa, A., Roca, D., Vidal, M., Pueyo, I., Conget, I., & Giménez, M. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01625-2 · Cited by 29
Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses
Nimri, R., Grosman, B., Roy, A., Nir, J., Fisch-Shvalb, N., Kurtz, N., Loewenthal, N., Gillon‐Keren, M., Muller, I., Atlas, E., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0448 · Cited by 31
Self-citationPemberton, J. S., Kershaw, M., Dias, R. P., Idkowiak, J., Mohamed, Z., Saraff, V., Barrett, T. G., Krone, R. E., & Uday, S. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13155 · Cited by 28
“9 mmol/L).(2) The consensus sets goals for CGM users to aim for; TBR2 <1%, TBR <4%, TIR ≥70%, TAR<25% and TAR2 <5%.”
BackgroundMethodInfluentialCommercialized Hybrid Closed-Loop System (Minimed Medtronic 670G) Results During Pregnancy
Moreno-Fernández, J., & García-Seco, J. A. (2021) · AACE Clinical Case Reports · doi:10.1016/j.aace.2020.11.039 · Cited by 30
van der Linden, J., Welsh, J. B., Hirsch, I. B., & Garg, S. K. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0649 · Cited by 27
Self-citationJulla, J., Jacquemier, P., Fagherazzi, G., Vidal-Trécan, T., Juddoo, V., Jaziri, A., Mersel, H., Venteclef, N., Roussel, R., Massin, P., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1847 · Cited by 26
Secher, A. L., Pedersen‐Bjergaard, U., Svendsen, O. L., Gade-Rasmussen, B., Almdal, T., RAIMOND, L. H., Vistisen, D., & Nørgaard, K. (2021) · Diabetologia · doi:10.1007/s00125-021-05555-8 · Cited by 29
Self-citationNew Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals
Jarosinski, M. A., Chen, Y., Varas, N., Dhayalan, B., Chatterjee, D., & Weiss, M. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab849 · Cited by 26
“Beyond hemoglobin A1c (HbA1c) as an indicator of mean glycemic control, the advent of continuous glucose monitoring (CGM) has enabled assessment of time in range (TiR) (14) and”
BackgroundDomínguez‐Riscart, J., Buero-Fernandez, N., García-Zarzuela, A., Morales-Perez, C., García-Ojanguren, A., & Lechuga-Sancho, A. M. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.813989 · Cited by 34
Insulinoterapia no diabetes mellitus tipo 1 (DM1)
Júnior, W. S. D. S., Gabbay, M. A. L., Lamounier, R. N., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-5 · Cited by 60
Mesa, A., Giménez, M., Pueyo, I., Perea, V., Viñals, C., Blanco, J., Vinagre, I., Serés‐Noriega, T., Boswell, L., Esmatjes, E., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109938 · Cited by 30
Diabetes: the role of continuous glucose monitoring
Kluemper, J. R., Smith, A. C., & Wobeter, B. R. (2022) · Drugs in Context · doi:10.7573/dic.2021-9-13 · Cited by 33
Gianini, A., Suklan, J., Skela‐Savič, B., Klemenčič, S., Battelino, T., Dovč, K., & Bratina, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.967725 · Cited by 27
Self-citationBrener, A., Hamama, S., Interator, H., Simon, A. B., Laurian, I., Dorfman, A., Chorna, E., Yackobovitch‐Gavan, M., Oren, A., Eyal, O., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3584 · Cited by 29
“These definitions are according to the international consensus on CGM interpretation.(25)”
BackgroundA Federated Learning-Inspired Evolutionary Algorithm: Application to Glucose Prediction
Falco, I. D., Cioppa, A. D., Koutný, T., Úbl, M., Krčma, M., Scafuri, U., & Tarantino, E. (2023) · Sensors · doi:10.3390/s23062957 · Cited by 36
“In clinical practice, Time-in-Range represents the time spent within a safe glucose-level range [30].”
BackgroundJendle, J., & Reznik, Y. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15087 · Cited by 26
Wang, Y., Lu, J., Ni, J., Wang, M., Shen, Y., Lu, W., Zhu, W., Bao, Y., Rodbard, D., Vigersky, R. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15068 · Cited by 33
Self-citationMatabuena, M., Pazos-Couselo, M., Alonso‐Sampedro, M., Fernández‐Merino, C., González‐Quintela, A., & Gudé, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-40949-1 · Cited by 33
“Among the many metrics that exist to quantify GV, CV is the most appropriate measure to identify short-term glycemic variability and levels for patients with diabetes should be kept below 36% 4 , although some studies recommend lower targets ( 33”
BackgroundPihoker, C., Shulman, D. I., Forlenza, G. P., Kaiserman, K. B., Sherr, J. L., Thrasher, J. R., Buckingham, B. A., Kipnes, M. S., Bode, B. W., Carlson, A. L., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0255 · Cited by 29
“Real-world analyses, 16,26 prospective observational studies, 7,9,27,28 and one RCT 12 have shown that pediatric use of the 100 mg/dL GT and 2-h AIT demonstrated greater likelihood of attaining consensus-recommended targets 4,29,30 for TIR, TBR, and TAR, in addition to A1C or GMI.”
Self-citationAutomated Insulin Delivery for Pregnant Women With Type 1 Diabetes: Where Do We Stand?
Benhalima, K., JENDLE, J. H., Beunen, K., & Ringholm, L. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231223934 · Cited by 28
“15 When using AID in pregnancy, TIRp might be more easily achieved, allowing for a lower upper target of 6.6 mmol/L or 120 mg/dL instead of 7.8 mmol/L or 140 mg/dL.”
InfluentialAktürk, H. K., Battelino, T., Castañeda, J., Arrieta, A., van den Heuvel, T. R. A., & Cohen, O. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0432 · Cited by 27
“41 Therefore, it is speculated that time spent in the 70–140 mg/dL range, introduced by the International Consensus statement as time in tight range (TITR), 18,19 can be a valuable metric to assess normoglycemia, and might be a more appropriate target for glycemia in T1D and T2D.”
InfluentialSelf-citationHelleputte, S., Backer, T. L. M. D., Lapauw, B., Shadid, S., Celie, B. M., Eetvelde, B. V., Wyngaert, K. V., & Calders, P. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3301 · Cited by 28
“comprise 5-minute interval glucose values from which all existing parameters can be calculated.(64,65) The 7-point capillary BG profile, on the other hand, used in the study of Lachin et al with data from the DCCT(43) is insufficient to characterize GV correctly as the validity of”
MethodAnxiety, depression, and glycemic control during Covid-19 pandemic in youths with type 1 diabetes
Cusinato, M., Martino, M., Sartori, A., Gabrielli, C., Tassara, L., Debertolis, G., Righetto, E., & Moretti, C. (2021) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2021-0153 · Cited by 30
“Secondary endpoints were percentage changes in TAR, TBR, GMI, CV [6], and the association between TAD scores and TIR.”
MethodInfluentialMiura, H., Sakaguchi, K., Otowa‐Suematsu, N., Yamada, T., So, A., Komada, H., Okada, Y., Hirota, Y., Tamori, Y., & Ogawa, W. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14161 · Cited by 25
“and TAR.(29) In the current study, TBR70 and TAR180 were longer and shorter, respectively, in the IDeg period than in the IGlarU300 period.”
MethodInfluentialResidual β-Cell Function Is Associated With Longer Time in Range in Individuals With Type 1 Diabetes
Snethlage, C. M. F., McDonald, T. J., Oram, R. A., de Groen, P., Rampanelli, E., Schimmel, A. W. M., Holleman, F., Siegelaar, S. E., Hoekstra, J. B. L., Brouwer, C. B., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0776 · Cited by 37
Zhu, T., Li, K., & Georgiou, P. (2023) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2023.3303367 · Cited by 50
“Accordingtotherecommendationsfromthe International Consensus [50], the clinical targets of BG control for adults and adolescents are > 70% and ∼ 60% , respectively.”
BackgroundMethodInfluentialChi, H., Song, M. J., Zhang, J., Zhou, J., & Liu, D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289782 · Cited by 31
Quirós, C., Herrera, M. T., Amigó, J., Wägner, A. M., Beato-Víbora, P. I., Azriel, S., Climent, E., Soldevila, B., Barquiel, B., Colomo, N., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0594 · Cited by 36
Langarica, S., de la Vega, D., Cariman, N., Hurtado, M. M., Andrade, D. C., Núñez, F., & Rodriguez-Fernández, M. (2024) · IEEE Open Journal of Engineering in Medicine and Biology · doi:10.1109/ojemb.2024.3365290 · Cited by 41
“While the target range should be personalized to meet each patient’s specific needs [3], the standard target for individuals with Type I Diabetes Mellitus (T1DM) is 70–180 mg/dl. Achieving this range involves weight management, regular physical activity, dietary control, and insulin administration.”
BackgroundUse of diabetes technology in children
Schoelwer, M. J., DeBoer, M. D., & Breton, M. D. (2024) · Diabetologia · doi:10.1007/s00125-024-06218-0 · Cited by 34
“[16].”
Cai, J., Liu, J., Lu, J., Ni, J., Wang, C., Chen, L., Lu, W., Zhu, W., Xia, T., & Zhou, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16212 · Cited by 30
“25 Thus, our findings may not be generalizable to populations with a high risk of hypoglycaemia.”
GLU: a software package for analysing continuously measured glucose levels in epidemiology
Millard, L. A. C., Patel, N., Tilling, K. M., Lewcock, M., Flach, P. A., & Lawlor, D. A. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa004 · Cited by 28
Lehmann, V., Zueger, T., Zeder, A., Scott, S., Bally, L., Laimer, M., & Stettler, C. (2020) · Diabetes Care · doi:10.2337/dc20-1560 · Cited by 20
Kjölhede, K., Berntorp, K. E., Kristensen, K. H., Katsarou, A., Shaat, N., Wiberg, N., Knop, F. K., Kristensen, L., Dotevall, A., Elfvin, A., et al. (2021) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14039 · Cited by 26
Toyoda, M., Murata, T., Saito, N., Kimura, M., Takahashi, H., Ishida, N., Kitamura, M., Hida, M., Hayashi, A., Moriguchi, I., et al. (2021) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13618 · Cited by 27
“As minimizing the TBR is recommended in the guideline [26], the TBR measured by FreeStyle Libre might mislead treatment decisions when used in patients undergoing HD.”
Method
Metadata
- Authors
- Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
- Affiliations
- University of Ljubljana (SI)
- Kinderkrankenhaus auf der Bult (DE)
- Park Nicollet Health Services (US)
- King's College London (GB)
- Jaeb Center for Health Research (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- American Diabetes Association (US)
- Close Concerns (United States) (US)
- University of Padua (IT)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Sydney (AU)
- Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
- University of Colorado Denver (US)
- Grunberger Diabetes Institute (US)
- University of Sheffield (GB)
- Science Consulting in Diabetes, Neuss, Germany
- University of Washington (US)
- University of Cambridge (GB)
- Shanghai Jiao Tong University (CN)
- University of Virginia (US)
- Breakthrough T1D (US)
- Joslin Diabetes Center (US)
- Endocrinology Research Center (RU)
- KU Leuven (BE)
- University of East Anglia (GB)
- Schneider Children's Medical Center (IL)
- Steno Diabetes Center Copenhagen (DK)
- CGParkin Communications, Inc., Henderson, NV
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
- Biomedical Informatics Consultants LLC, Potomac, MD
- DiaCare, Ahmedabad, Gujarat, India
- University of Florida (US)
- dQ&A Market Research, Inc., San Francisco, CA
- Nihon University (JP)
- Yale University (US)
- Tel Aviv University (IL)
- Corresponding author
- Battelino, Tadej
- ORCID
- Battelino, Tadej
- Danne, Thomas
- Bergenstal, Richard M.
- Amiel, Stephanie A.
- Beck, Roy
- Biester, Torben
- Bosi, Emanuele
- Buckingham, Bruce A.
- Cefalu, William T.
- Close, Kelly L.
- Cobelli, Claudio
- Dassau, Eyal
- DeVries, J. Hans
- Donaghue, Kim C.
- Doyle, Francis J.
- Garg, Satish
- Grunberger, George
- Heller, Simon
- Heinemann, Lutz
- Hirsch, Irl B.
- Hovorka, Roman
- Jia, Weiping
- Kordonouri, Olga
- Kovatchev, Boris
- Kowalski, Aaron
- Laffel, Lori
- Levine, Brian
- Mayorov, Alexander
- Mathieu, Chantal
- Murphy, Helen R.
- Nimri, Revital
- Nørgaard, Kirsten
- Parkin, Christopher G.
- Renard, Eric
- Rodbard, David
- Saboo, Banshi
- Schatz, Desmond
- Stoner, Keaton
- Urakami, Tatsuiko
- Weinzimer, Stuart A.
- Phillip, Moshe
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1593-1603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973648
- OpenAlex
- W2948261890
- Cited by
- 4,237
- References
- 96
- Citations by year
- 2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
- FWCI
- 215.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Insulet Corporation
- MannKind Corporation
- Dexcom
- OPKO Health
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
- Universiteit van Amsterdam
- KU Leuven
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- Abbott Diabetes Care
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
- MeSH terms
- Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.